Excellent tolerability but relatively low initial clinical efficacy of telcagepant in migraine

Headache

Volumn 51, Issue 1, 2011, Pages 118-123

  Tfelt Hansen, Peer ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

calcitonin gene related peptide antagonism; controlled clinical trials; meta analysis; migraine; telcagepant

Indexed keywords

ALMOTRIPTAN; CALCITONIN GENE RELATED PEPTIDE; PLACEBO; RIZATRIPTAN; SUMATRIPTAN; TELCAGEPANT; ZOLMITRIPTAN;

ANALGESIA; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FUNCTIONAL ASSESSMENT; HUMAN; META ANALYSIS (TOPIC); MIGRAINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECEPTOR BLOCKING; REVIEW; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AZEPINES; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HEADACHE; HUMANS; IMIDAZOLES; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; TREATMENT OUTCOME; TRYPTAMINES;

EID: 78650963413     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/j.1526-4610.2010.01797.x     Document Type: Review

References (25)

1. Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-trlated peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Eng J Med. 2004; 350: 1104-1110.
2. Ho TW, Mannix LK, Fan X, et al. Randomized controlled trial pf an oral CGRP receptor antagonist. MK-0974, in acute treatment of migraine. Neurology. 2008; 70: 1304-1212.
3. Ho TW, Ferrari MD, Dodick DW, et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compated with zolmitriptan for acute migraine: A randomized, placebo-controlled, parallel-treatment trial. Lancet. 2008; 372: 2115-2123.
4. Connor KM, Shapiro RE, Diener H-C, et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology. 2009; 73: 970-977.
5. Edvinsson L, Ho TW,. CGRP receptor antagonism and migraine. Neurotherapeutics. 2010; 7: 164-175.
6. Petersen KA, Birk S, Lassen LH, et al. The CGRP-antagonist, BIBN4096BS does not affect cerebral or systemic haemodynamics in healthy volunteers. Cephalalgia. 2005; 25: 139-147.
7. Tfelt-Hansen P, De Vries P, Saxena PR,. Triptans in migraine. A comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000; 60: 1259-1287.
8. 1B/1D agonists) in migraine: Detailed results and methods of a meta-analysis of 53 trials. Cephalalgia. 2002; 22: 633-658.
9. McCrory DC, Gray RN,. Oral sumatriptan for acute migraine. Cochrane Database Syst Rev. 2003;(3): CD002915.
10. Pascual J, Mateos V, Roig C, Sanchez-del-Rio M, Jiménez D,. Marketed oral triptans in the acute treatment of migraine: A systematic review on efficacy and tolerability. Headache. 2007; 47: 1152-1168.
11. Tfelt-Hansen P,. Efficacy and adverse events of subcutaneous, oral and intranasal sumatriptan used for migraine treatment: A systematic review based on number needed to treat. Cephalalgia. 1998; 18: 532-538.
12. Tfelt-Hansen P, Saxena PR, Dahlof C, et al. Ergotamine in the acute treatment of migraine-European Consensus. Brain. 2000; 123: 9-18.
13. Tfelt-Hansen P, Saxena PR,. Ergot alkaloids in the acute treatment of migraine. In:, Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins; 2006: 459-467.
14. Saxena PR, Tfelt-Hansen P,. Triptans, 5HT1B/1D agonists in the acute treatment of migraine. In:, Olesen J, Goadsby PJ, Ramadan NM, Tfelt-Hansen P, Welch KMA, eds. The Headaches, 3rd edn. Philadelphia: Lippincott Williams & Wilkins; 2006: 469-503.
15. Goadsby PJ, Edvinsson L,. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol. 1993; 33: 48-56.
16. Goadsby PJ, Edvinsson L, Ekman R,. Vasoactive peptide release in the extracerebral circulation of humans during migraine attacks. Ann Neurol. 1990; 28: 183-187.
17. Lassen LH, Haderslev PA, Jacobsen VB, Iversen HK, Speling B, Olesen J,. CGRP may play a causative role in migraine. Cephalalgia. 2002; 22: 54-61, 63.
18. Villalon CM, Olesen J,. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther. 2009; 124: 309-323.
19. Tvedskov JF, Lipka K, Ashina M, Iversen HK, Schifter S, Olesen J,. No increase of calcitonin gene-related peptide in jugular blood during migraine. Ann Neurol. 2005; 58: 561-563.
20. Tfelt-Hansen P, Le H,. Calcitonin gene-related peptide in blood: Is it increased in the external jugular vein during migraine and cluster headache attacks? A review. J Headache Pain. 2009; 10: 137-143.
21. Tfelt-Hansen P,. Migraine and telcagepant. Lancet. 2009; 373: 1003.
22. Lipton LB, Hammelsky SW, Dayno JM,. What do patients with migraine want from acute migraine treatment? Headache. 2002; 42 (Suppl. 1): 3-9.
23. Tfelt-Hansen P, Teall J, Rodriguez F, et al. Visser WH on behalf of the Rizatriptan 030 study Group. Oral rizatriptan versus oral sumatriptan: A direct comparative study in the acute treatment of migraine. Headache. 1998; 38: 748-755.
24. Cady RK, Wendt JK, Kirchner JR, Sargent JD, Rothrock JF, Skaggs H Jr,. Treatment of acute migraine with subcutaneous sumatriptan. JAMA. 1991; 265: 2831-2835.
25. Tfelt-Hansen P,. Is there an inherent limit to the efficacy of CGRP receptor antagonists in the acute treatment of migraine? A comment. J Headache Pain. 2009; 10: 389-391.